Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS)

Siva, Shankar; Louie, Alexander V; Kotecha, Rupesh; Barber, Melissa N; Ali, Muhammad; Zhang, Zhenwei; Guckenberger, Matthias; Kim, Mi-Sook; Scorsetti, Marta; Tree, Alison C; Slotman, Ben J; Sahgal, Arjun; Lo, Simon S

doi:10.1016/s1470-2045(23)00513-2

Cited by 25 publications

(1 citation statement)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In other solid tumors, radiotherapy has been certified to benefit patients with a tolerable safety profile. In patients with renal cell carcinoma who decline surgery, stereotactic body radiotherapy can be suggested as a safe and effective standard treatment option ( 18 ). In advanced lung cancer, the addition of radiotherapy significantly improved response rates compared with immunotherapy alone ( 19 ).…”

Section: Discussionmentioning

confidence: 99%

Emerging chemotherapy-based treatments in anaplastic thyroid cancer: an updated analysis of prospective studies

Wang,

Lin,

Kuang

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundFor patients with anaplastic thyroid cancer (ATC) without mutational driver genes, chemotherapy is suggested to be the first-line treatment option. However, the benefits of chemotherapy in treating ATC are limited. In this analysis, we collected the prospective data reported since 2010 to analyze the emerging chemotherapy-based treatments in ATC comprehensively.MethodsFor this updated analysis, we searched PubMed (MEDLINE), Web of Science, Embase, and Cochrane CENTRAL databases from 1 January 2010 to 7 February 2024 for prospective clinical studies that contained chemotherapy-based treatments. This analysis was done to pool overall survival (OS), progression-free survival (PFS), objective response rates (ORRs), disease control rates (DCRs), and grade 3 or worse treatment-related adverse events (TRAEs).ResultsSix prospective clinical trials with 232 patients were included. Chemotherapy was commonly combined with targeted therapy or radiotherapy. The pooled median OS was 6.0 months (95% CI 4.1–9.7), and the median PFS was 3.2 months (95% CI 1.9–6.0) in patients with ATC who received chemotherapy-based strategies. The integrated ORR and DCR were 21% (95% CI 15%–27%) and 64% (95% CI 55%–72%), respectively. Regarding the grade 3 or worse TRAE, the pooled incidence was 68% (95% CI 47%–86%).ConclusionAlthough the emerging chemotherapy-based treatments showed antitumor activity in patients with ATC, these strategies failed to prolong the survival time substantially. More practical, safe, and novel therapeutic regimens for patients with ATC warrant further investigations.

show abstract

Section: Discussionmentioning

confidence: 99%

Emerging chemotherapy-based treatments in anaplastic thyroid cancer: an updated analysis of prospective studies

Wang,

Lin,

Kuang

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

SBRT for primary kidney cancer: Data from the multicentre prospective FASTRACK II study

Morgenthaler,

Rühle,

Kirste

et al. 2024

Strahlenther Onkol

View full text Add to dashboard Cite

Hintergrund Die stereotaktische Körperstrahlentherapie (SBRT) wird als eine nicht-invasive Therapieoption zur Behandlung des primären Nierenzellkarzinoms (RCC) bei Patienten, die aus internistischen Gründen für eine Operation nicht geeignet sind oder diese ablehnen, postuliert. Ziel der multizentrischen FASTRACK II-Studie war es, die Wirksamkeit der SBRT beim RCC zu untersuchen [1].Patienten und Methoden Diese prospektive, nicht-randomisierte und multizentrische Phase-II-Studie wurde in sieben australischen Zentren und einem niederländischen Zentrum im Rahmen der Trans Tasman Radiation Oncology Group (TROG) und der Australien and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) durchgeführt. Eingeschlossen wurden Patienten, bei denen die Diagnose eines RCCs bioptisch gesichert wurde, deren ECOG-

show abstract

Stereotactic Body Radiotherapy: is less fractionation more effective in adrenal and renal malignant lesions?

Rivas,

de la Torre-Luque,

Moreno-Olmedo

et al. 2024

World J Urol

View full text Add to dashboard Cite

Purpose Stereotactic body radiotherapy (SBRT) has become an excellent non-invasive alternative for many patients with primary renal cell carcinoma (RCC) and adrenal malignancies (AM). The aims of this study were to analyse how tumor-, patient- and treatment-related factors may influence the outcomes and side effects of SBRT and to assess its benefits as an alternative to surgery. Methods This retrospective, multicenter study included 25 lesions in 23 patients treated with SBRT using different devices (LINAC, CyberKnife® and Tomotherapy®). A multivariate linear regression was used for the statistical study. Results Local control time was higher than six months in more than 87% of patients and treatment response was complete for 73.68%. There was an overall 2-year survival of 40% and none of the deaths were secondary to renal or adrenal local progression. Patients treated with lower total radiation dose (mean [m] = 55 Gy) but less fractions with more dose per fraction (> 8.5 Gy) showed better outcome. Patients with previous chemotherapy and surgery treatments also showed higher complete response and disease-free survival (> 6 months). Conclusions This study highlights the importance of ultra-hypofractionated regimens with higher doses per session. Thus, the referral of patients with RCC and AM to Radiotherapy and Oncology departments should be encouraged supporting the role of SBRT as a minimally invasive and outpatient treatment.

show abstract

Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS)

Cited by 25 publications

References 50 publications

Emerging chemotherapy-based treatments in anaplastic thyroid cancer: an updated analysis of prospective studies

Emerging chemotherapy-based treatments in anaplastic thyroid cancer: an updated analysis of prospective studies

SBRT for primary kidney cancer: Data from the multicentre prospective FASTRACK II study

Stereotactic Body Radiotherapy: is less fractionation more effective in adrenal and renal malignant lesions?

Contact Info

Product

Resources

About